ArticleTranslational cancer research2026
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although anti-disialoganglioside 2 (GD2) monoclonal antibodies have become the standard immounotherapy for high-risk petients, antigen escape and drug resistance still lead to relapse or suboptimal responses in some cases. This study aims to develop a novel bispecific antibody (BsAb) G/R-001, which specifically binds to both GD2 and receptor tyrosine kinase-like orphan receptor 1 (ROR1), for the treatment of NB and other tumors. Methods: G/R-001 BsAb (IgG1 subtype) was constructed by fusing anti-ROR1 scFv to the C-terminus of anti-GD2 heavy chain. G/R-001 was transiently expressed in HEK293 cells, purified by affinity chromatography, and characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for structure and purity. Enzyme-linked immunosorbent assay (ELISA) and flow cytometry were used to evaluate the binding capacity of G/R-001 to GD2 and ROR1. The Results: The theoretical molecular weight of G/R-001 was 198.82 kDa, with SDS-PAGE results showing high purity (the molecular weight of the intact antibody with glycosylation modification corresponded to approximately 248.68 kDa on non-reducing electrophoresis). Under reducing and non-reducing conditions, bands corresponding to heavy chain, light chain, and intact antibody were observed respectively. ELISA results showed that G/R-001 had a binding capacity of 12.1 nM for GD2 and 3.5 nM for hROR1. Flow cytometry further confirmed the specific binding of G/R-001 to GD2 and ROR1. LDH assay results showed that, compared with Naxitamab or Zilovertamab alone, G/R-001 exhibited significant cytotoxic activity against GD2 Conclusions: The G/R-001 BsAb can simultaneously bind to GD2 and ROR1, and shows significant anti-tumor activity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.